An Appraisal of 18-Fluorodeoxyglucose Positron Emission Tomography for Melanoma Staging

[en] BACKGROUND: Positron emission tomography (PET scan) using fluorodeoxyglucose (FDG) is increasingly recognized as a reliable diagnostic method to detect metastases of malignant melanoma (MM). OBJECTIVE: To compare the diagnostic performance of 18-FDG PET scan to that of conventional imaging. METHODS: A total of 28 assessments were conducted in 24 patients at risk of metastatic MM. Results: The diagnostic accuracy was over 80% and similar for PET scan and conventional imaging. CONCLUSION: Both the specificity and sensitivity of PET scan are high although not perfect. Confrontation of data with anatomical location and clinicopathological findings remains mandatory.

Disciplines :

Radiology, nuclear medicine & imaging
Dermatology

Author, co-author :

Paquet, Philippe ; Centre Hospitalier Universitaire de Liège - CHU > Dermatopathologie

Henry, Frédérique ; Université de Liège - ULiège > Département des sciences cliniques > Département des sciences cliniques

Belhocine, Tarik

Hustinx, Roland ; Université de Liège - ULiège > Département des sciences cliniques > Médecine nucléaire

Najjar, Fadi

Pierard-Franchimont, Claudine ; Université de Liège - ULiège > Département des sciences cliniques > Dermatopathologie

Pierard, Gérald ; Université de Liège - ULiège > Département des sciences cliniques > Dermatopathologie

Rigo, Pierre ; Université de Liège - ULiège > Département des sciences de la motricité > Pathologie générale et médecine nucléaire

Language :

English

Title :

An Appraisal of 18-Fluorodeoxyglucose Positron Emission Tomography for Melanoma Staging

Publication date :

2000

Journal title :

Dermatology

ISSN :

1018-8665

eISSN :

1421-9832

Publisher :

Karger, Basel, Switzerland

Volume :

200

Issue :

Pages :

167-9

Peer reviewed :

Peer Reviewed verified by ORBi

Available on ORBi :

since 28 January 2010

Statistics

Number of views

41 (0 by ULiège)

Number of downloads

0 (0 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

Bibliography

Wagner HN, Szabo Z, Buchanan JW: Nuclear medicine: What it is and what it does; in Wagner HN (ed): Principles of Nuclear Medicine. New York, Saunders, 1995, pp 1-8.
Wahl RL, Hutchins GD, Buchsbaum DJ: Fluorine-18-2-deoxy-2-fluoro-D-glucose (FDG) uptake into human tumor xenografts: Feasibility studies for cancer imaging with PET. Cancer 1991;76:1544-1549.
Warburg O: On the origin of cancer cells. Science 1956;123:309-314.
Hatanaka M: Transport of sugar in tumor cell membranes. Biochim Biophys Acta 1974;355: 77-104.
Weber G: Enzymology of cancer cells. N Engl J Med 1976;296:541-551.
Rigo P, Paulus P, Kaschten BJ, Hustinx R, Bury T, Jerusalem G, Benoît T, Foidart-Willems J: Oncological applications of positron emission tomography with fluorine-18 fluorodeoxyglycose. Eur J Nucl Med 1996;23:1641-1674.
Kern KA, Brunetti A, Norton JA, Chang AE, Malawer M, Lack E, Finn RD, Rosenberg SA, Larson SM: Metabolic imaging of human extremity musculo-skeletal tumors by PET. J Nucl Med 1988;29:181-186.
Dahlba M, Hoffman EJ, Hols CK: Whole-body positron emission tomography. Methods and performance characteristics. J Nucl Med 1992; 33:1191-1199.
Paquet P, Hustinx R, Rigo P, Piérard GE: Malignant melanoma staging using whole-body positron emission tomography (PET): A report of two cases illustrating the clinical usefulness of metabolic imaging. Melanoma Res 1998;8: 59-62.
Böni R, Böni RAH, Steinert H, Burg G, Buck A, Marincek B, Berthold T, Dummer R, Voellmy D, Ballmer B, von Schulthess GK: Staging of metastatic melanoma by whole-body positron emission tomography using 2-fluorine-18-fluoro-2-deoxy-D-glucose. Br J Dermatol 1995; 132:556-562.
Steinert HC, Boni RAH, Buck A, Böni R, Berthold T, Marincek B, Burg G, von Schulthess GK: Malignant melanoma: Staging with whole-body positron emission tomography and 2-(F-18)-fluoro-2-deoxy-D-glucose. Radiology 1995; 195:705-709.
Blessing C, Feine U, Geiger L, Carl M, Rassner G, Fierlbeck G: Positron emission tomography and ultrasonography. Arch Dermatol 1995; 131:1394-1398.
Gritters LS, Francis IR, Zasadny KR, Nahl RL: Initial assessment of positron emission tomography using 2-fluorine-18-fluoro-2-deoxy-D-glucose in the imaging of malignant melanoma. J Nucl Med 1993;34:1420-1427.
Pounds TR, Valk PE, Haseman MK, Myers RW, Lutrin CL: Whole-body PET-FDG imaging in diagnosis of metastatic melanoma: Comparison to CT. J Nucl Med 1995;36:116P.
Wöhrle H, Feine U, Geiger L, Blessing C, Laniado M, Friese S, Lietzenmayer R, Fierlbeck G, Müller-Schauenburg W: Whole-body 18-FDG PET in 46 patients with recurrent malignant melanomas: A comparison versus CT and MRI. Eur J Nucl Med 1995;22:753.